Effects of N 1-methylnicotinamide on oxidative and glycooxidative stress markers in rats with streptozotocin-induced diabetes mellitus

Redox Report

Volumn 17, Issue 1, 2012, Pages 1-7

  Országhová, Zuzana ^a   Uličná, Ol'ga ^a   Liptáková, Anna ^a   Žitňanová, Ingrid ^a   Muchová, Jana ^a   Watala, Cezary ^b   Ďuračková, Zdeňka ^a  

^a Bratislava   (Slovakia)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Diabetes mellitus; Glycooxidative stress; Methylnicotinamide; Oxidative stress; Protein carbonyls

Indexed keywords

1 METHYLNICOTINAMIDE; 8 HYDROXYGUANINE; ADVANCED GLYCATION END PRODUCT; CARBONYL DERIVATIVE; LIPID PEROXIDE; ANTIOXIDANT; BIOLOGICAL MARKER; DRUG DERIVATIVE; N(1) METHYLNICOTINAMIDE; N(1)-METHYLNICOTINAMIDE; NICOTINAMIDE; STREPTOZOCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DNA DAMAGE; DNA MODIFICATION; GLYCOOXIDATIVE STRESS; LIPID PEROXIDATION; LYMPHOCYTE; MALE; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; PROTEIN MODIFICATION; RAT; STREPTOZOCIN DIABETES; TREATMENT DURATION; ANIMAL; BLOOD; DRUG EFFECT; DRUG SCREENING; EXPERIMENTAL DIABETES MELLITUS; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY; PROTEIN CARBONYLATION; WISTAR RAT;

ANIMALS; ANTIOXIDANTS; BIOLOGICAL MARKERS; DIABETES MELLITUS, EXPERIMENTAL; DNA DAMAGE; DRUG EVALUATION, PRECLINICAL; GLYCOSYLATION END PRODUCTS, ADVANCED; LIPID PEROXIDATION; LIPID PEROXIDES; LYMPHOCYTES; MALE; NIACINAMIDE; OXIDATION-REDUCTION; OXIDATIVE STRESS; PROTEIN CARBONYLATION; RATS; RATS, WISTAR; STREPTOZOCIN;

EID: 84857321796     PISSN: 13510002     EISSN: 17432928     Source Type: Journal    
DOI: 10.1179/1351000211Y.0000000016     Document Type: Article

References (36)

1. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-20.
2. Van Dam PS, Van Asbek BS, Erkelens BW, Marx JJM, Gispen WH, Brevenboer B. The role of oxidative stress in neuropathy and other diabetic complications. Diabetes Metab Rev 1995;11:181-92.
3. Yamagishi S, Ueda S, Matsui T, Nakamura K, Okuda S. Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy. Curr Pharm Des 2008;14(10):962-8.
4. Muchová J, Liptáková A, Országhová Z, Garaiová I, Tisoň P, Čársky J, et al. Antioxidant systems in polymorphonuclear leucocytes of type 2 diabetes mellitus. Diabet Med 1999;16(1):74-8.
5. Boušová I, Martin J, Jahodář L, Dušek J, Palička V, Dršata J. Evaluation of in vitro effects of natural substances of plant origin using a model of protein glycoxidation. J Pharm Biomed Anal 2005;37:957-62.
6. Baynes JW, Thorpe SR. Glycoxidation and lipoxidation in atherogenesis. Free Radic Biol Med 2000;28:1708-16.
7. SartiniD, Santarelli A, Rossi V, GoteriG, Rubini C, CiavarellaD, et al. Nicotinamide N-methyltransferase upregulation inversely correlates with lymph node metastasis in oral squamous cell carcinoma. Mol Med 2007;13:415-21.
8. Williams AC, Ramsden DB. Nicotinamide homeostasis: a xenobiotic pathway that is key to development and degenerative diseases. Med Hypotheses 2005;65:353-62.
9. Klaidman L, Morales M, Kem S, Yang J, ChangML, Adams JD Jr. Nicotinamide offers multiple protective mechanisms in stroke as a precursor for NAD+, as a PARP inhibitor and by partial restoration of mitochondrial function. Pharmacology 2003;69:150-7.
10. O'Brien BA, Harmon BV, Cameron DP, Allan DJ. Nicotinamide prevents the development of diabetes in the cyclophosphamide-induced NOD mouse model by reducing beta-cell apoptosis. J Pathol 2000;191:86-92.
11. Aoyama K, Matsubara K, Okada K, Fukushima S, Shimizu K, Yamaguchi S, et al. N-methylation ability for azaheterocyclic amines is higher in Parkinson's disease: nicotinamide loading test. J Neural Transm 2000;107:985-95.
12. Wozniacka A, Wieczorkowska M, Gebicki J, Sysa-Jedrzejowska A. Topical application of 1-methylnicotinamide in the treatment of rosacea: a pilot study. Clin Exp Dermatol 2005;30:632-5.
13. Gebicki J, Sysa-Jedrzejowska A, Adamus J, et al. 1-Methylnicotinamide: a potent anti-inflammatory agent of vitamin origin. Pol J Pharmacol 2003;55:109-12.
14. Fischer LJ, Falany J, Fisher R. Characteristics of nicotinamide and N1-methylnicotinamide protection from alloxan diabetes in mice. Toxicol Appl Pharmacol 1983;70:148-55.
15. Adamiec M, Adamus J, Ciebiada I, Denys A, Gebicki J. Search for drugs of the combined anti-inflammatory and anti-bacterial properties: 1-methyl-N'-(hydroxymethyl) nicotinamide. Pharmacol Rep 2006;58:246-9.
16. Chlopicki S, Swies J, Mogielnicki A, Buczko W, Bartus M, Lomnicka M, et al. 1-Methylnicotinamide (MNA), a primary metabolite of nicotinamide, exerts antithrombotic activity mediated by COX-2/PGI2 pathway. Br J Pharmacol 2007;152: 230-9.
17. Ogata S, Takeuchi M, Teradaira S, Yamamoto N, Iwata K, Okumura K, et al. Radical scavenging activities of niacinrelated compounds. Biosci Biotechnol Biochem 2002;66(3): 641-5.
18. Shaw EN. Quaternary pyridinium compounds. In: Klingsberg E (ed.) Pyridine and its derivatives. New York: Interscience Publishers; 1961. p. 1-31.
19. Kalousová M, Škrha J, Zíma T. Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol Res 2002;51:597-604.
20. El-Saadani M, Esterbauer H, El-SayedM, Goher M, Nassar AY, Jürgens G. A spectrophotometric assay for lipid peroxides in serum lipoproteins using a commercially available reagent. J Lipid Res 1989;30:627-30.
21. Buss H, Chan TP, Sluis KB, Domigan NM, Winterbourn CC. Protein carbonyl measurement by a sensitive ELISA method. Free Radic Biol Med 1997;23(3):361-6.
22. Collins AR, Duthie SJ, Dobson VL. Direct enzymic detection of endogenous oxidative base damage in human lymphocyte DNA. Carcinogenesis 1993;14:1733-5.
23. Collins AR, Dobson VL, Dušinská M, Kennedy G, Štetina R. Comet assay: what can it really tell us? Mutat Res 1997;375: 183-93.
24. ESCODD, Gedik CM, Collins A. Establishing the background level of base oxidation in human lymphocyte DNA: results of an interlaboratory validation study. FASEB J 2004;18:1-23.
25. Re R, Pellegrini N, Proteggente A, Pannala A, Yang M, Rice-Evans C. Antioxidant activity applying an improved ABTS radical cation decolorization assay. Free Radic Biol Med 1999; 26(9/10):1231-7.
26. Gale EA, Bingley PJ, Emmett CL, Collier T, European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004;363(9413):925-31.
27. Biedroń R, Ciszek M, Tokarczyk M, Bobek M, Kurnyta M, Słominska EM, et al. 1-Methyl-nicotinamide and nicotinamide: two related anti-inflammatory agents that differentially affect the functions of activated macrophages. Arch Immunol Ther Exp 2008;56:127-34.
28. Ahmed N, Thornalley PJ. Quantitative screening of protein biomarkers of early glycation, advanced glycation, oxidation and nitrosation in cellular and extracellular proteins by tandem mass spectrometry multiple reaction monitoring. Biochem Soc Trans 2003;31(6):1417-22.
29. Watała C, Kaźmierczak P, Dobaczewski M, Przygodzki T, Bartus M, Lomnicka M, et al. Anti-diabetic effects of 1-methylnicotinamide (MNA) in streptozocin-induced diabetes in rats. Pharmacol Rep 2009;61:86-98.
30. Pan HZ, Zhang H, Chang D, Li H, Sui H. The change of oxidative stress products in diabetes mellitus and diabetic retinopathy. Br J Ophthalmol 2008;92:548-51.
31. Cakatay U. Protein oxidation parameters in type 2 diabetic patients with good and poor glycaemic control. Diabetes Metab 2005;31:551-7.
32. Vessby J, Basu S, Mohsen R, Berne C, Vessby B. Oxidative stress and antioxidant status in type 1 diabetes mellitus. J Intern Med 2002;251:69-76.
33. Willems D, Dorchy H, Dufrasne D. Serum antioxidant status and oxidized LDL in well-controlled young type 1 diabetic patients with and without subclinical complications. Atherosclerosis 1998;137:61-4.
34. Feillet C, Roche B, Tauveron I, Bayle D, Rock E, Borel P, et al. Susceptibility to oxidation and physicochemical properties of LDL in insulin-dependent diabetics. Atherosclerosis 1998;136: 405-7.
35. Dandona P, Thusu K, Cook S, Snyder B, Makowski J, Armstrong D, et al. Oxidative damage to DNA in diabetes mellitus. Lancet 1996;347:444-5.
36. Collins AR, Rašlová K, Somorovská M, Petrovská H, Ondrušová A, Vohnout B, et al. DNA damage in diabetes: correlation with a clinical marker. Free Radic Biol Med 1998;25(3): 373-7.